Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2020

Chaekal O-, Scaradavou A, Frenet EM, Albano MS, Cushing M, Desai P, et al. Adoptive immunotherapy with CB following chemotherapy for patients with refractory myeloid malignancy: chimerism and response. Blood Adv. 2020;4(20):5146-5156.

Izzo F, Lee SC, Poran A, Chaligne R, Gaiti F, Gross B, et al. DNA methylation disruption reshapes the hematopoietic differentiation landscape. Nat Genet. 2020;52(4):378-387.

Patel SS, Rodig SJ. Overview of Tissue Imaging Methods. Methods Mol Biol. 2020;2055:455-465.

Liu D, Shoag JE, Poliak D, Goueli RS, Ravikumar V, Redmond D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun. 2020;11(1):1987.

Solomon JP, Arcila ME. Molecular Diagnostics of Non-Hodgkin Lymphoma. Cancer J. 2020;26(3):186-194.

Galassi TV, Antman-Passig M, Yaari Z, Jessurun J, Schwartz RE, Heller DA. Long-term in vivo biocompatibility of single-walled carbon nanotubes. PLoS One. 2020;15(5):e0226791.

Stopsack KH, Gerke T, Zareba P, Pettersson A, Chowdhury D, Ebot EM, et al. Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. Carcinogenesis. 2020;41(7):904-908.

Showalter K, Magro C, Zhang Y, Spiera R, Orange DE, Gordon JK. Response to: 'Correspondence on 'Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement'' by Manetti. Ann Rheum Dis. 2020.

Adams EJ, Karthaus WR, Hoover E, Liu D, Gruet A, Zhang Z, et al. Author Correction: FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2020;585(7826):E20.

Shanmugakani RK, Srinivasan B, Glesby MJ, Westblade LF, Cárdenas WB, Raj T, et al. Current state of the art in rapid diagnostics for antimicrobial resistance. Lab Chip. 2020;20(15):2607-2625.